scholarly article | Q13442814 |
P356 | DOI | 10.1188/03.ONF.E40-E47 |
P953 | full work available at URL | http://ons.metapress.com/index/H760703496561442.pdf |
P698 | PubMed publication ID | 12692669 |
P2093 | author name string | Judith Luce | |
Karen Casey | |||
Brenda Nussey | |||
Jill Isreal | |||
Suzanne L. Dibble | |||
P2860 | cites work | Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology | Q33880234 |
Economics and health-related quality of life in antiemetic therapy: recommendations for trial design | Q33994104 | ||
Treatment of chemotherapy-induced nausea and vomiting | Q34286849 | ||
The effectiveness of relaxation training in reducing treatment-related symptoms and improving emotional adjustment in acute non-surgical cancer treatment: a meta-analytical review | Q34465002 | ||
Improved control of emesis and quality of life with ondansetron in breast cancer | Q40890387 | ||
The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: a randomised controlled trial | Q43924288 | ||
Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration | Q47965348 | ||
Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. | Q52526734 | ||
Options in the treatment of chemotherapy-induced emesis. | Q53567949 | ||
Mechanisms and management of nausea and emesis | Q71221209 | ||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | chemotherapy | Q974135 |
P304 | page(s) | E40-7 | |
P577 | publication date | 2003-03-01 | |
P1433 | published in | Oncology Nursing Forum | Q15760549 |
P1476 | title | Delayed Chemotherapy-Induced Nausea in Women Treated for Breast Cancer | |
P478 | volume | 30 |
Q37190499 | A review of patient self-report tools for chemotherapy-induced nausea and vomiting |
Q24188141 | Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting |
Q24246243 | Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting |
Q37337769 | Body image disturbance and surgical decision making in egyptian post menopausal breast cancer patients |
Q43250798 | Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy |
Q34572539 | Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings |
Q46133386 | Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide |
Q64929253 | Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy. |
Q40299605 | Distress before chemotherapy predicts delayed but not acute nausea |
Q24244208 | Exercise for women receiving adjuvant therapy for breast cancer |
Q24246529 | Exercises for women receiving adjuvant therapy for breast cancer |
Q41151846 | Guideline sheets on the side effects of anticancer drugs are useful for general practitioners |
Q33652946 | Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis |
Q37736060 | Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists |
Q39224398 | Translation and psychometric assessment of the Persian version of the Rhodes Index of Nausea, Vomiting and Retching (INVR) scale for the assessment of chemotherapy-induced nausea and vomiting. |
Search more.